BACKGROUND: Cord blood transplant (CBT) recipients have a high incidence of herpes zoster (HZ) in the context of short-term peritransplant antiviral prophylaxis. In 2009, international guidelines recommended HZ prophylaxis for at least 1 year after hematopoietic cell transplant. The impact of longer-term antiviral prophylaxis on HZ incidence after CBT is unknown. METHODS: We retrospectively analyzed varicella zoster virus (VZV)-seropositive CBT recipients who were transplanted between 2006 and 2016. We abstracted HZ events and other variables for up to 5 years post-CBT. We calculated the cumulative incidence of HZ and used Cox proportional hazards regression to identify variables associated with HZ. RESULTS: The study cohort consisted of 227 patients. Among 1-year survivors, 91% were still receiving prophylaxis, for a median duration of 20.6 months. HZ occurred in 44 patients (19%) at a median of 23.6 months. The cumulative incidence of HZ by 1 year after CBT was 1.8% (95% confidence interval [CI], .1%-4%), but increased to 26% (95% CI, 19%-33%) by 5 years. In a multivariable analysis, acute graft-vs-host disease was associated with increased risk, whereas antiviral prophylaxis was associated with reduced risk for HZ (adjusted hazard ratio, 0.19 [95% CI, .09-.4]). There was no association between CD4+ T-cell counts at 1 year post-CBT and subsequent risk for HZ. CONCLUSIONS: We found a high incidence of HZ after CBT despite antiviral prophylaxis for > 1 year. Based on these findings, we suggest longer duration of prophylaxis for HZ after CBT. Compliance with antiviral prophylaxis, VZV-specific immune monitoring, and vaccination to mitigate HZ after CBT also require further study.
BACKGROUND: Cord blood transplant (CBT) recipients have a high incidence of herpes zoster (HZ) in the context of short-term peritransplant antiviral prophylaxis. In 2009, international guidelines recommended HZ prophylaxis for at least 1 year after hematopoietic cell transplant. The impact of longer-term antiviral prophylaxis on HZ incidence after CBT is unknown. METHODS: We retrospectively analyzed varicella zoster virus (VZV)-seropositive CBT recipients who were transplanted between 2006 and 2016. We abstracted HZ events and other variables for up to 5 years post-CBT. We calculated the cumulative incidence of HZ and used Cox proportional hazards regression to identify variables associated with HZ. RESULTS: The study cohort consisted of 227 patients. Among 1-year survivors, 91% were still receiving prophylaxis, for a median duration of 20.6 months. HZ occurred in 44 patients (19%) at a median of 23.6 months. The cumulative incidence of HZ by 1 year after CBT was 1.8% (95% confidence interval [CI], .1%-4%), but increased to 26% (95% CI, 19%-33%) by 5 years. In a multivariable analysis, acute graft-vs-host disease was associated with increased risk, whereas antiviral prophylaxis was associated with reduced risk for HZ (adjusted hazard ratio, 0.19 [95% CI, .09-.4]). There was no association between CD4+ T-cell counts at 1 year post-CBT and subsequent risk for HZ. CONCLUSIONS: We found a high incidence of HZ after CBT despite antiviral prophylaxis for > 1 year. Based on these findings, we suggest longer duration of prophylaxis for HZ after CBT. Compliance with antiviral prophylaxis, VZV-specific immune monitoring, and vaccination to mitigate HZ after CBT also require further study.
Authors: Y Koc; K B Miller; D P Schenkein; J Griffith; M Akhtar; J DesJardin; D R Snydman Journal: Biol Blood Marrow Transplant Date: 2000 Impact factor: 5.742
Authors: Drew J Winston; Kathleen M Mullane; Oliver A Cornely; Michael J Boeckh; Janice Wes Brown; Steven A Pergam; Igoris Trociukas; Pavel Žák; Michael D Craig; Genovefa A Papanicolaou; Juan D Velez; Jens Panse; Kimberly Hurtado; Doreen A Fernsler; Jon E Stek; Lei Pang; Shu-Chih Su; Yanli Zhao; Ivan S F Chan; Susan S Kaplan; Janie Parrino; Ingi Lee; Zoran Popmihajlov; Paula W Annunziato; Ann Arvin Journal: Lancet Date: 2018-05-24 Impact factor: 79.321
Authors: K Oshima; T Takahashi; T Mori; T Matsuyama; K Usuki; Y Asano-Mori; F Nakahara; S Okamoto; M Kurokawa; Y Kanda Journal: Transpl Infect Dis Date: 2010-10 Impact factor: 2.228
Authors: Adriana Bastidas; Javier de la Serna; Mohamed El Idrissi; Lidia Oostvogels; Philippe Quittet; Javier López-Jiménez; Filiz Vural; David Pohlreich; Tsila Zuckerman; Nicolas C Issa; Gianluca Gaidano; Je-Jung Lee; Sunil Abhyankar; Carlos Solano; Jaime Perez de Oteyza; Michael J Satlin; Stefan Schwartz; Magda Campins; Alberto Rocci; Carlos Vallejo Llamas; Dong-Gun Lee; Sen Mui Tan; Anna M Johnston; Andrew Grigg; Michael J Boeckh; Laura Campora; Marta Lopez-Fauqued; Thomas C Heineman; Edward A Stadtmauer; Keith M Sullivan Journal: JAMA Date: 2019-07-09 Impact factor: 56.272
Authors: Y Kanda; S Mineishi; T Saito; A Saito; S Yamada; M Ohnishi; A Chizuka; H Niiya; K Suenaga; K Nakai; T Takeuchi; A Makimoto; R Tanosaki; M Kami; Y Tanaka; S Fujita; T Watanabe; Y Kobayashi; K Tobinai; Y Takaue Journal: Bone Marrow Transplant Date: 2001-10 Impact factor: 5.483
Authors: Ola Blennow; Gustav Fjaertoft; Jacek Winiarski; Per Ljungman; Jonas Mattsson; Mats Remberger Journal: Biol Blood Marrow Transplant Date: 2014-06-07 Impact factor: 5.742
Authors: Jose F Camargo; Rick Y Lin; Yoichiro Natori; Anthony D Anderson; Maritza C Alencar; Trent P Wang; Michele I Morris; Krishna V Komanduri Journal: Blood Adv Date: 2020-10-13